Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status

Eur J Clin Invest 2011; 41 (10): 1133–1148 Background  Aggressive pituitary tumours are associated with substantial morbidity and mortality. Treatment options are often limited, and chemotherapy has been reserved as salvage therapy although historically results have often been disappointing. However...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of clinical investigation Vol. 41; no. 10; pp. 1133 - 1148
Main Authors McCormack, Ann I., Wass, John A. H., Grossman, Ashley B.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.10.2011
Wiley-Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Eur J Clin Invest 2011; 41 (10): 1133–1148 Background  Aggressive pituitary tumours are associated with substantial morbidity and mortality. Treatment options are often limited, and chemotherapy has been reserved as salvage therapy although historically results have often been disappointing. However, temozolomide, an oral alkylating agent, has recently demonstrated significant activity against these tumours. A DNA repair protein, 06‐methylguanine‐DNA methyltransferase (MGMT) has been suggested as a biomarker to predict response to temozolomide in pituitary tumours. Materials and methods  This paper will review the current literature on temozolomide and pituitary tumours and discuss the recent controversy surrounding the value of determining the MGMT status in this tumour group. A PubMed search was performed to retrieve articles, using the terms ‘pituitary tumour’ and ‘temozolomide’. Results  Overall, 24/40 (60%) of the published cases demonstrated a response to temozolomide therapy. The highest response rates were seen amongst prolactinomas (73%) and ACTH‐secreting tumours (60%), whilst nonfunctioning pituitary tumours exhibit lower response rates (40%). Responsivity is typically evident in the first 3 months of therapy and may be dramatic and sustained. Low MGMT expression, as determined by immunohistochemistry, is associated with a high response rate (76%), whilst high MGMT expression has not been associated with responses. MGMT promoter methylation does not correlate with temozolomide response. Conclusions  Temozolomide is the first chemotherapeutic agent to show substantial response rates in aggressive pituitary tumours. MGMT immunohistochemistry, but not MGMT methylation analysis, shows promise as a predictive tool. Prospective clinical trials are now necessary to more accurately determine the efficacy of this agent in this patient group.
Bibliography:ark:/67375/WNG-GJ1ZXH8W-K
ArticleID:ECI2520
istex:7ED5DEEB61BD6D6A0566A0A6BC58B45FC511A6C6
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0014-2972
1365-2362
DOI:10.1111/j.1365-2362.2011.02520.x